Amended Summary Notice of Proposed Settlement of The Altair Nanotechnologies, Inc. Shareholder Derivative Litigation
17.3.2017 13:00 | NASDAQ OMX
UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK
In re Altair Nanotechnologies Shareholder
CASE NO.: 14-CV-09418-TPG-HBP
RENO, Nev., March 17, 2017 (GLOBE NEWSWIRE) -- PLEASE BE ADVISED that Plaintiffs and the Settling Defendants have reached a settlement (the “Settlement”) to resolve the issues raised in the above-captioned consolidated derivative action (“Action”) (capitalized terms are defined in the Stipulation of Settlement dated July 22, 2016, and Amendment No. 1 to the Stipulation, dated January 18, 2017 (collectively, the “Settlement Stipulation”)).
PLEASE BE FURTHER ADVISED that pursuant to an Order of the United States District Court for the Southern District of New York (the “Court”), a hearing (the “Settlement Hearing”) will be held before the Honorable Thomas P. Griesa in the United States District Court for the Southern District of New York, 500 Pearl Street, Courtroom 26B, New York, New York 10007, at 2:00 p.m. on August 10, 2017, to determine whether (i) the proposed settlement should be approved by the Court as fair, reasonable, adequate, and in the best interests of Altair Nanotechnologies, Inc. (“Altair” or the “Company”) and Altair shareholders; (ii) the Action should be dismissed with prejudice and all Released Claims against the Released Persons should be released and extinguished; (iii) the Court should award attorneys’ fees and expenses to Plaintiffs’ Counsel and incentive awards to Plaintiffs; and (iv) to consider such other matters as may properly come before the Court. The Settlement Hearing may be continued by the Court at the Settlement Hearing, or at any adjourned session thereof without further notice. The Action and Settlement address claims alleging that certain current and former directors and officers of Altair breached their fiduciary duties by failing to implement and/or maintain adequate internal controls over the Company’s operations and disclosures, by making or approving false statements to the Company’s shareholders, by grossly mismanaging the Company, and by wasting Altair’s assets by causing the Company to incur significant potential liability for legal costs, penalties, fines and/or legal fees in connection with the defense of the Individual Defendants’ unlawful course of conduct. The Action further alleges that certain Defendants were unjustly enriched at the Company’s expense. The Settling Defendants deny and continue to deny all allegations of wrongdoing and deny that Defendants have any liability on the claims asserted in the Action.
As part of the Settlement, Altair has agreed to adopt and/or maintain certain corporate governance reforms as set forth in the Settlement Stipulation. The terms and conditions of the proposed Settlement are set forth in the Settlement Stipulation and Addendum thereto. The Settlement Stipulation and amended Exhibits thereto have been filed with the Court.
Plaintiffs’ Counsel will request Court approval of the agreed upon attorneys’ fees and expenses in an amount not to exceed $150,000, which shall include all attorneys’ fees and costs that may be due any counsel (or anyone else) who has asserted, or participated in the assertion of, derivative claims on behalf of Altair in any court. Any award of fees and expenses will be paid by the Company (or its insurer on its behalf). To date, Plaintiffs’ Counsel have neither received any payment for their services in conducting the Action, nor have counsel been reimbursed for their out-of-pocket expenses incurred. Plaintiffs will also seek Court approval of an incentive payment of up to $1,500 each for their participation and efforts in the Action. This Incentive Amount shall be paid from the attorneys’ fees and expenses awarded by the Court. If the Settlement is approved, the Action will be dismissed with prejudice and the Defendants will be released by Plaintiffs, Altair, and its shareholders from all claims that were or could have been alleged in the Action.
If you are a current Altair Shareholder, you may have certain rights in connection with the proposed settlement. The full and complete Notice along with the Settlement Stipulation have been made accessible on Altair’s corporate website: http://www.altairnano.com/investors/. If you are a current Altair shareholder and do not take steps to appear in this Action or to object to the Settlement, you will be bound by the Court’s Judgment and Order of Dismissal, you will forever be barred from raising an objection to such Settlement in this or any other action or proceeding, and certain claims that you might have may be released.
PLEASE DO NOT TELEPHONE THE COURT OR ALTAIR REGARDING THIS NOTICE.
Karen Werner, firstname.lastname@example.org
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
ZIM Adds MatchBack Systems Analytics Services in Italy21.8.2017 22:00 | Pressemelding
Innovative approach to gain efficiencies through fewer empty container moves adds significant value for ZIM's customers GREEN BAY, Wis. and ROTTERDAM, The Netherlands, Aug. 21, 2017 (GLOBE NEWSWIRE) -- MatchBack Systems, Inc. ( www.matchbacksystems.com ), the leading software as a service (SaaS) solution to plan, optimize and automate matchbacks, announced that ZIM Integrated Shipping Ltd. joined the company's customer base on May 1, 2017 to optimize their inland operation in Italy. The account will be serviced through the European office in Rotterdam and corporate headquarters in North America. The system will be deployed for a 2 months pilot after which the parties will evaluate the scope for a broader cooperation. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1cb9a632-22a4-4ff5-a3d5-d8b3964e5113 Gil Lehmann, Head of Global Land Tra
Promethean Opens New Global Headquarters in Seattle18.8.2017 18:38 | Pressemelding
Seattle, Wash., Aug. 18, 2017 (GLOBE NEWSWIRE) -- PrometheanTM, a global education technology company, announced today the opening of its new global headquarters in Seattle, Wash. Promethean's office in Atlanta, Ga. will continue to serve as the hub for the Americas markets, and the Blackburn, U.K. office will continue to carry on as the hub for the EMEA markets and parts of Asia. Promethean is one of the leading brands in the international education technology market with more than 20 years of experience in the K-12 classroom. Its solutions are in more than 50,000 schools and institutions in 154 countries. "As traditional pedagogy continues to move towards immersive learning, it's important for Promethean to lead innovation in education with the latest technology," said Vin Riera, CEO of Promethean. "Seattle is a global technology hub, and establishing Promethean's global headquarters there increases opportunities for new business models, concepts
Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00 | Pressemelding
Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50 | Pressemelding
NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market. I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30 | Pressemelding
WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00 | Pressemelding
RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium DR Capsules 49.3 mg in the coming weeks Esomeprazole Strontium DR Capsules 49.3 mg will be the third commercial GI product to be promoted by RedHill in the U.S. RedHill's GI-focused sales force currently promotes two GI s
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom